suxamethonium Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
quaternary ammonium compounds 2489 306-40-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • suxamethonium chloride
  • succinylcholine
  • suxamethonium
  • dicholine succinate
  • succinic acid dicholine diester
  • succinocholine
  • succinoylcholine
  • succinylbischoline
  • succinylcholine chloride
A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.
  • Molecular weight: 290.40
  • Formula: C14H30N2O4
  • CLOGP: -6.87
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 52.60
  • ALOGS: -5.68
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Aug. 20, 1952 FDA SANDOZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 229.72 115.90 46 436 4240 2353363
Cardiac arrest 201.77 115.90 52 430 14878 2342725
Hyperthermia malignant 198.29 115.90 26 456 144 2357459
Exposure during pregnancy 197.05 115.90 57 425 25162 2332441
Hypotension 174.42 115.90 55 427 32381 2325222
Anaphylactic reaction 166.45 115.90 41 441 9664 2347939
Maternal exposure during pregnancy 130.64 115.90 37 445 14826 2342777

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperthermia malignant 291.85 153.25 41 364 288 1746088

Pharmacologic Action:

SourceCodeDescription
ATC M03AB01 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
Choline derivatives
FDA EPC N0000175719 Depolarizing Neuromuscular Blocker
FDA PE N0000175733 Neuromuscular Depolarizing Blockade
CHEBI has role CHEBI:51371 muscle relaxant
CHEBI has role CHEBI:88188 drug allergen
CHEBI has role CHEBI:51372 neuromuscular agent
MeSH PA D009465 Neuromuscular Agents
MeSH PA D009466 Neuromuscular Blocking Agents
MeSH PA D009467 Neuromuscular Depolarizing Agents
MeSH PA D018373 Peripheral Nervous System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Muscle relaxation, function indication 11977004
General anesthesia indication 50697003
Skeletal Muscle Relaxation for Endotracheal Intubation indication
Ocular hypertension contraindication 4210003 DOID:9282
Hypocalcemia contraindication 5291005
Poisoning by digitalis glycoside contraindication 12876009
Hyperkalemia contraindication 14140009
Glaucoma contraindication 23986001 DOID:1686
Infectious disease contraindication 40733004
Myxedema contraindication 43153006 DOID:11634
Hypokalemia contraindication 43339004
Burn injury contraindication 48333001
Bradycardia contraindication 48867003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Muscular dystrophy contraindication 73297009 DOID:9884
Duchenne muscular dystrophy contraindication 76670001 DOID:11723
Third degree burn injury contraindication 80247002
Spinal cord injury contraindication 90584004
Myasthenia gravis contraindication 91637004 DOID:437
Fracture of bone contraindication 125605004
Disorder of muscle contraindication 129565002 DOID:423
Spasticity contraindication 221360009
Rhabdomyolysis contraindication 240131006
Anemia contraindication 271737000 DOID:2355
Injury of eye region contraindication 282752000
Deficiency of cholinesterase contraindication 360607009
At risk for aspiration contraindication 371736008
Primary malignant neoplasm contraindication 372087000
Surgical procedure on eye proper contraindication 373353005
Fever contraindication 386661006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Malignant hyperthermia contraindication 405501007
Cardiac arrest contraindication 410429000 DOID:0060319
Traumatic injury contraindication 417746004
Cardiac Decompensation contraindication

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscle-type nicotinic acetylcholine receptor Ion channel AGONIST CHEMBL CHEMBL
Acetylcholinesterase Enzyme Ki 4.68 CHEMBL

External reference:

IDSource
4017730 VUID
N0000178917 NUI
C0012792 UMLSCUI
D00766 KEGG_DRUG
3822002 SNOMEDCT_US
4019935 VANDF
372724004 SNOMEDCT_US
10154 RXNORM
d00376 MMSL
005590 NDDF
CHEBI:45652 CHEBI
CHEMBL703 ChEMBL_ID
CHEMBL983 ChEMBL_ID
DB00202 DRUGBANK_ID
I9L0DDD30I UNII
26 INN_ID
71-27-2 SECONDARY_CAS_RN
5314 PUBCHEM_CID
D013390 MESH_DESCRIPTOR_UI
4004 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Quelicin HUMAN PRESCRIPTION DRUG LABEL 1 0409-6629 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 13 sections
QUELICIN HUMAN PRESCRIPTION DRUG LABEL 1 0409-6970 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 13 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-3009 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 13 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-3411 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 13 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-9053 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 13 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 49396-0152 INJECTION 200 mg PARENTERAL ANDA 2 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1353 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 13 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51991-964 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 13 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 52584-097 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 12 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 52584-377 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 13 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 69918-700 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 13 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 70069-301 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 12 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 70121-1581 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 13 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 70710-1377 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 13 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 70771-1352 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 13 sections
Quelicin HUMAN PRESCRIPTION DRUG LABEL 1 71872-7026 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 13 sections
Quelicin HUMAN PRESCRIPTION DRUG LABEL 1 71872-7146 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 13 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 71872-7166 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 13 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 71872-7167 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 13 sections